Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 10CNS 9Other hematologic neoplasm 7Thoracic 6Plasma cell 6Lymphoid 6Head & Neck 6Gastrointestinal 6Endocrine 4Tumor-Agnostic 3Sarcoma 2Other solid neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Neoplasm Metastasis 2Sarcoma 1Osteosarcoma 1

Interventions

Specimen Handling 36Magnetic Resonance Spectroscopy 31Cyclophosphamide 26Doxorubicin 23Biopsy 22pembrolizumab 21Temozolomide 21X-Rays 17Radiotherapy 17Radiation 16Nivolumab 13atezolizumab 12Vincristine 12Phantoms, Imaging 12Irinotecan 12Ifosfamide 12Gemcitabine 12fludarabine 11cabozantinib 10liposomal doxorubicin 8Surgical Procedures, Operative 8Ipilimumab 8Etoposide 8Bevacizumab 8Paclitaxel 7Immunoglobulin G 7Carboplatin 7palbociclib 6olaparib 6fludarabine phosphate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
trametinib × Sarcoma × 90 days × Clear all
NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed
603 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡